AN2 Therapeutics, Inc. (ANTX) has 49 open-market insider trades by 17 insiders since 2022. Over the last six months insiders net sold $16K. The most active filer is Eric Easom, CEO.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Peter Kolchinsky | 10% Owner | — | 1 | $25.0M | 2022-03-29 |
| RA Capital Nexus Fund II, L.P. | 10% Owner | — | 3 | $17.5M | 2023-08-18 |
| Kabeer Aziz | Dir | — | 6 | $8.3M | 2026-10-12 |
| RA Capital Healthcare Fund LP | 10% Owner | — | 1 | $7.6M | 2024-08-09 |
| Braden Michael Leonard | 10% Owner | — | 3 | $5.0M | 2025-05-30 |
| Robin Shane Readnour | Dir | — | 4 | $2.6M | 2026-09-09 |
| Adjuvant Capital Management, LLC via Kabeer Aziz | 10% Owner | — | 1 | $2.0M | 2024-01-16 |
| Joseph S. Zakrzewski | Dir | — | 3 | $1.9M | 2026-08-14 |
| Eric Easom | CEO | — | 8 | $1.3M | 2026-02-20 |
| Joshua M. Eizen | — | — | 4 | $66K | 2026-07-08 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Robin Shane Readnour | Director | Sell | $7K | 2026-09-09 |
| Robin Shane Readnour | Director | Sell | $97K | 2026-09-03 |
| Margaret M. FitzPatrick | Director | Buy | $12K | 2026-09-01 |
| Sarah Joanne Williams | CAO | Sell | $2K | 2026-09-01 |
| Robin Shane Readnour | Director | Sell | $213K | 2026-08-17 |
| Joshua M. Eizen | — | Sell | $25K |
Companies that share insiders with ANTX, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2026-07-08 |
| Sarah Joanne Williams | CAO | Sell | $1K | 2026-05-29 |
| Sarah Joanne Williams | Principal Accounting Officer | Sell | $347 | 2026-03-03 |
| Joshua M. Eizen | — | Sell | $25K | 2026-01-05 |
| Stephen David Prior | Chief Strategy Officer | Sell | $6K | 2026-01-05 |
| Sanjay Chanda | Chief Development Officer | Sell | $9K | 2026-01-05 |
| Lucy Day | CFO | Sell | $9K | 2026-01-05 |
| Stephen David Prior | Chief Strategy Officer | Sell | $872 | 2025-11-04 |
| Joshua M. Eizen | — | Sell | $3K | 2025-11-04 |
| Eric Easom | CEO | Buy | $11K | 2025-06-02 |